Glossary of peptide terminology: difference between revisions
Diff·revision 12 → 13·02:54, 25 Mar 2025
Difference between revision 12 and revision 13 of Glossary of peptide terminology. 10 lines changed; the page grew by 990 bytes.
| Revision 12 — 03:44, 28 Feb 2025 ColdChainCleo (talk) de-orphan 3,581 bytes ±0 | Revision 13 — 02:54, 25 Mar 2025 BaselineBex (talk) expand §Analysis and documentation 4,571 bytes +990 | ||
|---|---|---|---|
| 35 | ; Stability-indicating : Of a method, able to resolve degradation products from the parent.{{r|usp621}} | 35 | ; Stability-indicating : Of a method, able to resolve degradation products from the parent.{{r|usp621}} |
| 36 | 36 | ||
| + | 37 | == Clinical and evidence == | |
| + | 38 | ; [[Placebo-adjusted effect|Placebo-adjusted]] : The difference between treatment and comparator arms. | |
| + | 39 | ; [[Intention-to-treat analysis|ITT]] : Analysis by randomised assignment, regardless of treatment received. | |
| + | 40 | ; [[Number needed to treat|NNT]] : Reciprocal of the absolute risk reduction, over a stated period. | |
| + | 41 | ; [[Surrogate endpoint|Surrogate endpoint]] : A measure standing in for an outcome of direct importance. | |
| + | 42 | ; Estimand : A precise statement of the quantity a trial estimates, including how discontinuation is handled. | |
| + | 43 | ; Contraindication : A circumstance in which labelling directs a product is not used; distinct from a warning. | |
| + | 44 | ; [[Research use only|Research use only]] : A presentation, not a quality grade; such material is not approved for human use.{{r|drucker2018}} | |
| + | 45 | ||
| 37 | == References == | 46 | == References == |
| 38 | {{reflist}} | 47 | {{reflist}} |
| 39 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | 48 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> |
| 40 | <ref name="usp621">United States Pharmacopeia, General Chapter <621>, ''Chromatography''.</ref> | 49 | <ref name="usp621">United States Pharmacopeia, General Chapter <621>, ''Chromatography''.</ref> |
| + | 50 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> | |
| 41 | <ref name="reports">PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see [[Project:Sourcing_guidelines]]).</ref> | 51 | <ref name="reports">PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see [[Project:Sourcing_guidelines]]).</ref> |
| 42 | 52 |